Boston Scientific CRM audit
This article was originally published in The Gray Sheet
Firm anticipates FDA inspections of cardiac rhythm management facilities impacted by a December 2005 warning letter to Guidant to begin in the "coming weeks," CEO Jim Tobin said Oct. 18 during the firm's third-quarter earnings call (1"The Gray Sheet" Jan. 2, 2006, p. 3). The company is "ready," he says...
You may also be interested in...
Guidant's board of directors has formally endorsed Johnson & Johnson's $21.5 bil. takeover bid while simultaneously agreeing to enter into discussions with Boston Scientific on its $25 bil. competing offer
A report from the US FDA says the agency will focus on updating its premarket submission portal, training staff and taking additional steps to start taking in applications for ASCA pilot participant sponsors.
With a late-stage compound on its hands, MGB is currently in discussions with several biotech and pharma companies and also with venture capitalists to continue late-stage development of a novel antibiotic which could transform treatment of Clostridium difficile.